Advertisement

Russian Chemical Bulletin

, Volume 68, Issue 5, pp 1122–1124 | Cite as

Inhibition of acid phospholipase A1 activity by the complex of tris(2-hydroxyethyl)amine with zinc bis(2-methylphenoxyacetate)

  • K. A. AbzaevaEmail author
  • M. M. Rasulov
  • I. V. Zhigacheva
Brief Communications
  • 4 Downloads

Abstract

Studies in the atherosclerosis model in rabbits showed that the complex of tris(2-hydroxyethyl)amine with zinc bis(2-methylphenoxyacetate) (zincatrane) modulates lipid metabolism in the liver and reduces activity of a lysosomal lipolytic enzyme of the hydrolase class. Zincatrane was proposed for use as an acid phospholipase A1 inhibitor to increase the resistance of the vascular system to cholesterol and prevent atherosclerosis.

Key words

acid phospholipase A1 atherosclerosis zincatrane 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. N. Bogdanova, Ph. D. (Medicine) Thesis, Scientific Research Institute of Nutrition, Russian Academy of Medical Sciences, Moscow, 1992, 28 pp. (in Russian).Google Scholar
  2. 2.
    D. M. Aronov, V. P. Lupanov, Ateroskleroz i koronarnaya bolezn’ serdtsa [Atherosclerosis and Coronary Heart Disease], Triada-Kh, Moscow, 2009, 358 pp. (in Russian).Google Scholar
  3. 3.
    H. Brockerhof, R. Jensen, Lipolytic Enzymes, Academic Press, 1974, 342 pp.Google Scholar
  4. 4.
    Pat. RF 2418580; Byul. Izobret. [Inventor Bull.], 2011, 14 (in Russian).Google Scholar
  5. 5.
    Pat. RF 2545888; Byul. Izobret. [Inventor Bull.], 2015, 10 (in Russian).Google Scholar
  6. 6.
    N. N. Anichkov, I. S. Zavodskaya, E. V. Moreva, Z. I. Vede-neeva, Neirogennye distrofi i i ikh farmakoterapiya [Neurogenic Dystrophies and Their Pharmacotherapy], Meditsina, Leningrad, 1968, 238 pp. (in Russian).Google Scholar
  7. 7.
    A. N. Klimov, V. E. Ryzhenkov, Eksperimental'noe izuchenie gipolipidemicheskikh i antiateroskleroticheskikh sredstv (meto-dicheskie rekomendatsii) [Experimental Studies of Hypolipide-mic and Antiatherosclerotic Drug (Methodical Guidelines)], Minzdrav SSSR, Pharmacology Committee, Moscow, 1988, 62 pp. (in Russian).Google Scholar
  8. 8.
    A. F. Robertson, W. E. M. Leuds, Biochemistry, 1962, 804–810.Google Scholar
  9. 9.
    J. Jaeken, M. Detheux, L. Van Maldergem, M. Foulon, H. Carchon, E. Van Schaftingen, Arch. Dis. Child., 1996, 74, 542–545.CrossRefGoogle Scholar
  10. 10.
    A. V. Pogozheva, Serdechno-sosudistye zabolevaniya [Cardiovascular Diseases], In-t pitaniya RAMN, Moscow, 2005, 288 pp. (in Russian).Google Scholar
  11. 11.
    V. A. Nagornev, Patogenez ateroskleroza [Pathogenesis of Atherosclerosis], Khromis, St. Petersburg, 2006, 265 pp. (in Russian).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2019

Authors and Affiliations

  • K. A. Abzaeva
    • 1
    Email author
  • M. M. Rasulov
    • 2
  • I. V. Zhigacheva
    • 3
  1. 1.A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of SciencesIrkutskRussian Federation
  2. 2.State Research Institute of Chemistry and Technology of Organoelement CompoundsMoscowRussian Federation
  3. 3.N. M. Emanuel Institute of Biochemical Physics, Russian Academy of SciencesMoscowRussian Federation

Personalised recommendations